secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001104659-26-001097
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models
--------------------------------------------------------------------------------

- Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.
- TTX-MC138 induced 5-fold increase in apoptotic activity and statistically significant survival extension.
- IND-enabling studies completed; TTX-MC138 already in Phase 1a for metastatic solid tumors.
- Phase 2a clinical trial for TTX-MC138 anticipated to begin in first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926001097/0001104659-26-001097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926001097/tm261878d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer